mp3 dönüştür

We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Maximizing RRMM strategy time at doctor appointments

Diane Kennedy, an RRMM caregiver advocate, explains how families can participate in shared decision-making with their care team. The post Maximizing RRMM strategy time at doctor appointments appeared first on Rare Cancer News. Read More

Don’t underestimate organization’s importance in RRMM care

Cindy Capps, an RRMM caregiver advocate, shares how learning about treatment options and staying organized helped her navigate complex care decisions.   The post Don’t underestimate organization’s importance in RRMM care appeared first on Rare Cancer News. Read...

Embrace the toughest RRMM conversations ASAP

Thomas Goode, an RRMM patient advocate, explains why patients should have honest conversations early about relapse and long-term care planning.   The post Embrace the toughest RRMM conversations ASAP appeared first on Rare Cancer News. Read More

A lay of the land in evolving RRMM treatment options

Sheri Baker, an RRMM patient advocate, discusses how treatment approaches for relapsed multiple myeloma have evolved over time. The post A lay of the land in evolving RRMM treatment options appeared first on Rare Cancer News. Read More

New registry aims to support research for pediatric acute myeloid leukemia

Tempus AI, a technology company focused on advancing precision medicine using artificial intelligence (AI), has announced a strategic collaboration with the advocacy organization Blood Cancer United to develop a comprehensive, patient-centered registry for children...
Latest Data

Latest Publications

Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia

Cancer Treat Res Commun. 2026 Feb 28;47:101161. doi: 10.1016/j.ctarc.2026.101161. Online ahead of...

Assessment tools for peripheral neuropathy in multiple myeloma

Korean J Intern Med. 2026 Mar;41(2):230-241. doi: 10.3904/kjim.2025.281. Epub 2026 Mar 1. ABSTRACT...

Early intervention for high-risk smoldering multiple myeloma (SMM)

Cochrane Database Syst Rev. 2026 Mar 18;3:CD015494. doi: 10.1002/14651858.CD015494.pub2. ABSTRACT...

Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis

Ann Med. 2026 Dec;58(1):2641930. doi: 10.1080/07853890.2026.2641930. Epub 2026 Mar 12. ABSTRACT...

Email

info@myeloma360.com

bahisliongalabet1xbet